Parallel Advisors’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Parallel Advisors’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.81K	Hold	200	–	–	﹤0.01%	2980
2025 Q4	$5.24K	Buy	+200	New	+$5.14K	﹤0.01%	2830
2025 Q2	–	Sell	-3	Closed	-$63	–	3624
2025 Q1	$63	Buy	+3	New	+$67	﹤0.01%	3460
2022 Q2	–	Sell	-332	Closed	-$12K	–	3147
2022 Q1	$12K	Sell	332 -836	-72%	-$29.5K	﹤0.01%	1927
2021 Q4	$51K	Buy	1,168 +836	+252%	+$39.6K	﹤0.01%	1307
2021 Q3	$17K	Buy	332 +98	+42%	+$5.11K	﹤0.01%	1823
2021 Q2	$12K	Sell	234 -523	-69%	-$24.5K	﹤0.01%	1930
2021 Q1	$35K	Hold	757	–	–	﹤0.01%	1337
2020 Q4	$35K	Sell	757 -93	-11%	-$4.01K	﹤0.01%	1239
2020 Q3	$33K	Buy	850 +93	+12%	+$3.58K	﹤0.01%	1242
2020 Q2	$28K	Buy	+757	New	+$25.6K	﹤0.01%	1279

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CCA

Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Parallel Advisors's IDNA Position: Q1 2026 in Review

Parallel Advisors held its iShares Genomics Immunology and Healthcare ETF (IDNA) position steady in Q1 2026 at 200 shares worth $5.81K. The position accounts for ﹤0.01% of the portfolio, ranked #2980.

Parallel Advisors first reported a position in IDNA in Q2 2020 and has held it in 11 quarters since. The position peaked at $51K in Q4 2021. 60 funds tracked by Wall St. Rank hold IDNA as of Q1 2026.

Parallel Advisors held 200 shares of iShares Genomics Immunology and Healthcare ETF worth $5.81K as of Q1 2026.
Parallel Advisors left its iShares Genomics Immunology and Healthcare ETF share count unchanged in Q1 2026.
iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #2980 holding.
Parallel Advisors first reported a position in iShares Genomics Immunology and Healthcare ETF in Q2 2020 and has held it in 11 quarters since.
Parallel Advisors's iShares Genomics Immunology and Healthcare ETF position peaked at $51K in Q4 2021.
60 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.